Synergy CRO

srgcro.com

Since 2002, SRG provides support to the pharmaceutical, biotechnology and medical device industries with a comprehensive range of collaborative services and solutions. In order to help our clients meet their clinical research goals we constantly explore and implement new ways to evolve the drug development process as well as look for cost-effective solutions. Through this work, we have come to value and respect up to date technologies along with time-tested traditional solutions. Loyalty to traditions, Openness to innovation With its unique philosophic mindset, Synergy is now the leading full-service contract research organization (CRO).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

PHARMA TECH HOLDINGS SA OBTAINS A CAPITAL COMMITMENT AGREEMENT OF CHF 30 MILLION FROM GLOBAL INVESTOR LDA CAPITAL

Pharma Tech | August 09, 2022

news image

Pharma Tech Holding SA announced it has secured a CHF 30 million investment to support its portfolio investments from LDA Capital Ltd, a global investment group with expertise in cross border transactions including the agriculture, Agri-tech, and CBD industries. Established in 2019, PTH is a Swiss based holding company, which invests into innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech...

Read More

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

news image

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More

BUSINESS INSIGHTS

LONG ISLAND UNIVERSITY EXTENDS PARTNERSHIP WITH DASSAULT SYSTÈMES TO INNOVATION AND RESEARCH IN LIFE SCIENCES

Long Island University | March 23, 2022

news image

Long Island University announced a new research and innovation partnership with Dassault Systèmes in life sciences. The partnership will focus on research with high societal impact to advance the fields of pharmaceutical sciences, precision medicine and health care in the digital age. Research includes precision medicine using "Virtual Twins," or exact digital models of human anatomy being developed by LIU and Dassault Systèmes; pandemic preparedness and th...

Read More

RESEARCH

ORSINI SPECIALTY PHARMACY EXPANDS COLLABORATES WITH ALNYLAM® PHARMACEUTICALS AS A LIMITED DISTRIBUTION PARTNER FOR OXLUMO™

Orsini | December 04, 2020

news image

Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effec...

Read More
news image

BUSINESS INSIGHTS

PHARMA TECH HOLDINGS SA OBTAINS A CAPITAL COMMITMENT AGREEMENT OF CHF 30 MILLION FROM GLOBAL INVESTOR LDA CAPITAL

Pharma Tech | August 09, 2022

Pharma Tech Holding SA announced it has secured a CHF 30 million investment to support its portfolio investments from LDA Capital Ltd, a global investment group with expertise in cross border transactions including the agriculture, Agri-tech, and CBD industries. Established in 2019, PTH is a Swiss based holding company, which invests into innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech...

Read More
news image

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More
news image

BUSINESS INSIGHTS

LONG ISLAND UNIVERSITY EXTENDS PARTNERSHIP WITH DASSAULT SYSTÈMES TO INNOVATION AND RESEARCH IN LIFE SCIENCES

Long Island University | March 23, 2022

Long Island University announced a new research and innovation partnership with Dassault Systèmes in life sciences. The partnership will focus on research with high societal impact to advance the fields of pharmaceutical sciences, precision medicine and health care in the digital age. Research includes precision medicine using "Virtual Twins," or exact digital models of human anatomy being developed by LIU and Dassault Systèmes; pandemic preparedness and th...

Read More
news image

RESEARCH

ORSINI SPECIALTY PHARMACY EXPANDS COLLABORATES WITH ALNYLAM® PHARMACEUTICALS AS A LIMITED DISTRIBUTION PARTNER FOR OXLUMO™

Orsini | December 04, 2020

Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effec...

Read More